Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York. Show more
Location: 19 Vestry Street, New York, NY, 10013, United States | Website: https://brightmindsbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
306.7M
52 Wk Range
$0.94 - $79.02
Previous Close
$43.27
Open
$44.65
Volume
458,263
Day Range
$41.57 - $46.44
Enterprise Value
241.1M
Cash
51.39M
Avg Qtr Burn
-1.972M
Insider Ownership
22.42%
Institutional Own.
73.99%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMB-101 Details Epilepsy, Developmental and Epileptic Encephalopathy | Phase 2 Data readout |